Skip to main content

Home/ Cancer/ Group items tagged cyclophosphamide

Rss Feed Group items tagged

Matti Narkia

Inhibition of suppressor T lymphocytes (Ts) by cimetidine. - J Immunol. 1987 May - 0 views

  •  
    Inhibition of suppressor T lymphocytes (Ts) by cimetidine. Sahasrabudhe DM, McCune CS, O'Donnell RW, Henshaw EC. J Immunol. 1987 May 1;138(9):2760-3. PMID: 2952721 Cyclophosphamide (CY) is the most extensively studied inhibitor of suppressor T lymphocyte (Ts) function. However, repeated administration of CY can abrogate sensitization. Therefore, we were interested in identifying noncytotoxic inhibitors of Ts function as adjuncts in the immunotherapy of Ts-inducing murine tumors. The effect of cimetidine (a histamine type 2 receptor antagonist) and diphenhydramine (a histamine type 1 receptor antagonist) on the Ts mediating tolerance to 2,4-dinitrofluorobenzene was studied. We report our data regarding the specific inhibition of Ts by cimetidine.
Matti Narkia

In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membr... - 0 views

  •  
    In vitro and in vivo immunomodulating and immunorestorative effects of Astragalus membranaceus. Cho WC, Leung KN. J Ethnopharmacol. 2007 Aug 15;113(1):132-41. Epub 2007 May 31. PMID: 17611061 doi:10.1016/j.jep.2007.05.020    
Matti Narkia

Combination Immunotherapy of Squamous Cell Carcinoma of the Head and Neck: A Phase 2 Tr... - 0 views

  •  
    Combination immunotherapy of squamous cell carcinoma of the head and neck: a phase 2 trial. Barrera JL, Verastegui E, Meneses A, Zinser J, de la Garza J, Hadden JW. Arch Otolaryngol Head Neck Surg. 2000 Mar;126(3):345-51. PMID: 10722007
1 - 3 of 3
Showing 20 items per page